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Abstract
We analysed the 12-week virological response to protease inhibi-
tor (PI) or non-nucleoside reverse transcriptase inhibitor
(NNRTI) therapy in 1108 patients carrying B or non-B human
immunodeﬁciency virus (HIV)-1 subtypes with matched resistance
mutation patterns. Response rates were not signiﬁcantly different
for non-B and B subtypes stratiﬁed for treatment status (51.5% vs.
41.5% in naı¨ve patients; 46.7% vs. 38.7% in experienced patients)
or regimens (46.9% vs. 39.7% with PI; 56.7% vs. 40% with NNRTI).
No difference in response was detected in patients harbouring B
and non-B subtypes with any resistance proﬁle. Further studies
are advisable to fully test this approach on larger datasets.
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Introduction
The majority of data on highly active antiretroviral therapy
(HAART) efﬁcacy and resistance to antiretroviral drugs have
been obtained from clinical trials involving mainly patients
harbouring human immunodeﬁciency virus (HIV)-1 subtype B
virus. However, non-B subtypes are highly prevalent world-
wide, and non-B subtypes are expanding in areas previously
homogeneous for subtype B [1–5].
Previous studies did not show signiﬁcant variations in viro-
logical and immunological responses to HAART between
subtype B and all non-B subtypes grouped together [6–10].
Few studies have addressed treatment response with speciﬁc
subtypes [11–14].
Moreover, even though most of the resistance-associated
mutations characterized in subtype B viruses are also found
in treatment-failing patients harbouring non-B subtypes
[15,16], some differences have been documented between
different subtypes [17,18].
Our aim was to explore a novel approach to compare the
impact of speciﬁc patterns of mutations on virological
response to treatment in patients harbouring different HIV-1
subtypes.
Methods
Details of the patients included in this analysis were obtained
from the Antiretroviral Resistance Cohort Analysis database.
Patient cases were selected on the basis of availability of
baseline HIV-1 genotype obtained at a maximum of 12 weeks
before starting or changing regimen and availability of a
12-week (range: 8–16 weeks) follow-up HIV-1 RNA determi-
nation. Response to therapy was deﬁned as viral load sup-
pression below 50 HIV-1 RNA copies/mL at week 12.
Subtyping was based on a partial HIV-1 pol sequence, as pre-
viously reported [3].
HIV-1 genotype was coded as a vector derived from the
following conditions: occurrence of any thymidine analogue
mutation (K65R, L74I/V, Q151M, 69ins, and M184I/V), any
major non-nucleoside reverse transcriptase inhibitor
(NNRTI) mutation (K103N/S, Y181C/I/V, Y188C/H/L, and
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G190A/E/S/T), and number (0, 1–3, or >3) of major protease
inhibitor (PI) mutations (D30N, I47A/V, G48V, I50L/V, I54L/
M, L76V, V82A/F/L/S/T, N88D/S, I84V, and L90M). Response
to therapy was evaluated in patients carrying either non-B or
B subtypes after their assignment to a ﬁnal vector combining
resistance pattern and treatment type.
Distributions of individuals were compared with the use
of the chi-squared test or Fisher exact test (categorical
parameters) and standard non-parametric methods (non-cate-
gorical parameters). The crude and Mantel–Haenszel-adjusted
ORs of response to therapy with 95% CIs were calculated in
univariate and multivariate analyses.
Results
The study included 1108 HIV-1-positive individuals referred
to 65 clinical centres of 13 Italian regions in the period
1997–2009. Of these patients, 126 (11.4%) harboured non-B
subtypes, represented by CRF02_AG (20.6%), F1 (19.8%), C
(15.9%), A (7.9%), G (7.1%), unique recombinant forms
(6.3%), and others (22.3%), as shown in Fig. 1.
The prevalence of non-B subtypes was higher among drug-
naı¨ve than among drug-experienced patients (20.7% vs. 7.6%,
respectively; p <0.0001). The demographic, immunological and
virological data of the patients stratiﬁed between naı¨ve and
experienced individuals are shown in Table 1A. No difference
in the proportion of drug resistance was observed between
non-B and B subtypes when they were grouped according to
naı¨ve or previously experienced individuals (Table 1B). Nota-
bly, no difference in transmitted drug resistance between sub-
jects carrying non-B and B subtypes was observed.
Complete previous treatment history was available for 424
patients. All of these subjects were NRTI-experienced, and
53 and 109 patients had previously received NNRTI-contain-
ing or PI-containing therapy, respectively; 232 received both
NNRTIs and PIs. Overall, there were 883 subjects beginning
a PI-based HAART regimen, of whom 31.8% had previously
received PI treatment. Among these individuals, 54.5%
(n = 153), 36.3% (n = 102) and 9.2% (n = 26) harboured a
virus population carrying 0, 1–3 and >3 major protease muta-
tions before starting or changing therapy. An antiretroviral
regimen containing an NNRTI was started in 225 individuals,
seven of whom had a transmitted NNRTI mutation.
As shown in Fig. 2, the proportion of subjects achieving vi-
rological suppression was higher among individuals carrying
non-B subtypes than among those carrying subtype B (49.2%
vs. 39.4%, p 0.035). This association was not linked to treat-
FIG. 2 Proportions of subjects achieving vir-
ological suppression at the median week 12.
Proportions of virological suppression are
shown among the overall population and naı¨ve
or experienced subjects, starting an anti-
retroviral regimen including a protease inhi-
bitor (PI) or a non-nucleoside reverse
transcriptase inhibitor (NNRTI).
FIG. 1 Distribution of non-B subtypes detec-
ted in 126 patients of the study population.
*Other non-B clades were CRF01_AE (n = 5),
CRF12_BF (n = 4), CRF06_cpx (n = 4),
CRF15_01B (n = 3), CRF10_CD (n = 2),
CRF09_cpx (n = 2), CRF13_cpx (n = 1),
CRF20_BG (n = 1), CRF28_BF (n = 1),
CRF31_BC (n = 1).
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ment status and type, and the statistical signiﬁcance was lost
in the subgroup analyses considering groups of drug-naı¨ve
(51.5% vs. 41.5%) or pretreated individuals (46.7% vs. 38.7%)
and PI-based regimens (46.9% vs. 39.7%) or NNRTI-based
regimens (56.7% vs. 40%).
Predictors of virological suppression in the univariate anal-
ysis included subtype (for non-B subtypes: OR 1.49,
95% CI 1.02–2.16; p 0.035), viral load at baseline (per 1 log
higher: OR 0.55, 95% CI 0.47–0.65; p <0.0001), time of
virological follow-up (per 1 week higher: OR 1.01,
95% CI 1.00–1.11; p 0.051), number of previous regimens
(per one regimen higher: OR 0.95, 95% CI 0.92–0.97;
p <0.0001), and calendar year (per 1 year later: OR 1.21,
95% CI 1.14–1.28; p <0.0001). By contrast, ethnicity, mode
of transmission, gender and age, NNRTI-containing regimen
or PI-containing regimen did not inﬂuence the outcome of
therapy. In the multivariate model, baseline viral load (per
1 log higher: OR 0.41, 95% CI 0.34–0.50; p <0.0001), num-
ber of previous regimens (per one regimen higher: OR 0.92,
95% CI 0.89–0.95; p <0.0001) and calendar year (per 1 year
later: OR 1.27, 95% CI 1.19–1.37; p <0.0001) remained sig-
niﬁcant predictors of virological success. The procedure used
to code HIV-1 genotype generated 35 and 12 vectors for
PI-treated and NNRTI-treated patients, respectively. Table 2
shows the patterns of mutations identiﬁed and the propor-
tions of patients infected with B or non-B subtypes who
achieved virological success. Among patients on PI-based or
NNRTI-based regimens, the rate of virological response was
not different between subtype B and non-B subtypes for any
of the evaluated resistance patterns.
Patients harbouring a wild-type HIV-1 genotype (vector 1)
and beginning PI-based HAART were the only group allowing
comparisons between subtype B and some of the individual
non-B subtypes. No signiﬁcant difference was observed in
this group when subtypes F1 and C were compared with
subtype B (response rates of 23.1% and 44.4% vs. 36.7%,
respectively). By contrast, a better response in patients car-
rying CRF02_AG (n = 12) than in those with subtype B
(75.0% vs. 36.7%, p 0.012) was observed.
Discussion
In the overall population, we observed a better response to
HAART with non-B subtypes, independently of treatment
status at baseline and use of NNRTI-based or PI-based therapy.
TABLE 1. Characteristics of the study population and drug resistance at baseline: (A) demographic, virological and immuno-
logical features of the 1108 patients; (B) prevalence of drug resistance before the beginning of a new highly active antiretrovi-
ral therapy regimen in naı¨ve and experienced subjects, according to subtype
Overall population
Naı¨ve patients Experienced patients
B Non-B p B Non-B p
(A)
Ethnic group, % (n)
Europeans 77.3 (856) 81.4 (206) 56.1 (37) <0.0001a 79.4 (579) 65.7 (34) <0.0001a
Africans 3.0 (33) 0.8 (2) 21.2 (14) 0.1 (1) 26.7(16)
Latin Americans 2.4 (27) 4.0 (10) 1.5 (1) 1.9 (14) 3.3 (2)
Asians 0.5 (6) 1.2 (3) 1.5 (1) 0.3 (2) 0
NA 16.8 (186) 12.6 (32) 0.2 (13) 18.2 (123) 13.3 (8)
Risk factor, % (n)
Heterosexual sex 48 (532) 58.9 (149) 78.8 (52) 0.013a 38.4 (280) 85.0 (51) <0.0001a
Men having sex with men 20.4 (226) 29.3 (74) 12.1 (8) 19.3 (141) 5.0 (3)
Intravenous drug use 28 (310) 9.1 (23) 6.1 (4) 38.5 (281) 3.3 (2)
Otherb 3.6 (40) 2.8 (7) 3.3 (2) 3.7 (27) 6.7 (4)
Gender, % (n)
Males 68.8 (758) 73.9 (184) 60.6 (40) 0.046a 69.74 (507) 45.0 (27) <0.0001a
Age (years), median (IQR) 40 (36–45) 41 (34–47) 35 (32–41) 0.001c 41 (37–45) 36.5 (32–46) 0.001c
HIV-1 RNA (log copies/mL), median (IQR) 4.6 (3.9–5.2) 5.1 (4.7–5.5) 4.9 (4.2–5.4) 0.049c 4.3 (3.7–5) 4.3 (3.9–4.7) NSc
CD4 count (cells/lL), median (IQR) 237 (118–380) 198 (64–323) 182 (64–286) NSc 262 (150–411) 209 (101–317) 0.029c
(B)
Any resistance, % (n) 57.0 (631) 9.9 (25) 6.1 (4) NSa 76.9 (561) 68.3 (41) NSa
NRTI resistance, % (n) 52.0 (576) 7.5 (19) 6.1 (4) NSa 70.6 (515) 63.3 (38) NSa
NNRTI resistance, % (n) 28.7 (318) 3. 2 (8) 4.6 (3) NSa 39.4 (287) 33.3 (20) NSa
PI resistance, % (n) 24.3 (269) 2.8 (7) 0 NSa 33.3 (243) 31.7 (19) NSa
Number of previous drug regimens, median (IQR) 3 (0–7) – – – 5 (3–8) 3 (1–7) 0.001c
Total patients, % (n) 100 (1108) 79.3 (253) 20.7 (66) – 92.4 (729) 7.6 (60) –
HIV, human immunodeﬁciency virus; NA, not available; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor;
NS, not signiﬁcant; IQR, interquartile range; PI, protease inhibitor.
aChi squared test.
bOther: professional risk, transfusions, vertical transmission.
cWilcoxon test (ns: not signiﬁcant).
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However, no difference was found according to subtype
after stratiﬁcation for treatment status. Response to treat-
ment has been previously analysed with subtype B viruses as
compared with non-B subtypes considered as a single cumu-
lative group [6–10]. This approach may mask differences
among speciﬁc subtypes in disease progression and drug sus-
ceptibility. Indeed, few studies have investigated treatment
response with speciﬁc subtypes [11,12]. Some reports indi-
cated subtype-independent effects of HAART, whereas other
studies suggested that subtype D, as compared with sub-
types C and A, negatively impacts on disease progression
and response to treatment [13,14].
Our data indicate that the efﬁcacy of NNRTI-containing
or PI-containing HAART is similar with B and non-B subtypes
when the same resistance pattern is detected. Response to
therapy with speciﬁc non-B subtypes was difﬁcult to analyse,
owing to the limited number of cases. However, subtypes F1
and C appear to respond similarly to subtype B, supporting
previous results and extending them to subtype F1 [13].
However, viral suppression was achieved in a higher propor-
tion of HIV genotype-matched patients harbouring
CRF02_AG. This result is compatible with a possible inﬂu-
ence of subtype-speciﬁc polymorphisms on the treatment
outcome. Although it has been previously suggested that cer-
tain polymorphisms can negatively impact on the outcome of
patients with non-B subtypes [19,20], our ﬁndings indicate
that HIV-1 pol minor mutations and polymorphisms do not
signiﬁcantly reduce the response to HAART. These data are
in agreement with a recent paper indicating that minor
changes not belonging to known resistance mutations are
not predictors of development of resistance in non-B sub-
types [16].
Owing to its retrospective nature, our study has several
limitations, particularly the lack of any information about
adherence to treatment. However, a number of factors pos-
sibly affecting adherence, such as ethnicity, age, gender, and
risk factors, were considered as possible confounders in our
regression model. None of these covariates had a detectable
impact on the virological outcome of patients stratiﬁed
according to treatment status in the multivariate analysis.
A limited proportion of subjects in our study achieved
viral suppression on therapy. This result may be partly
explained by: (i) the high proportion (more than 30%) of
patients with HIV-1 viral load above 105 copies/mL; and (ii)
the relatively short follow-up, which was deliberately chosen
to focus on the impact of genotype on virological response.
This study provides a new methodological approach for the
evaluation of HAART efﬁcacy in non-B subtypes as compared
with subtype B based on coding and matching for baseline
genotype. It cannot be ruled out that speciﬁc combinations of
mutations and speciﬁc polymorphisms exert different effects
on drug susceptibility with a particular subtype, and larger
datasets are required to deﬁnitively determine this.
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TABLE 2. Resistance patterns and response to treatment in patients carrying non-B and B subtypes
Vectors
Mutation pattern Subtype Response to HAART
Any TAM K65R L74V Q151M M184V PI mutationsa Non-B, % (n) B, % (n) Non-B, % (n) B, % (n)
1 0 0 0 0 0 0 15.4 (59) 84.6 (324) 40.7 (24) 36.7 (119)
2 0 0 0 0 1 0 13.2 (9) 86.8 (59) 44.4 (4) 57.6 (34)
3 1 0 0 0 0 0 4.4 (4) 95.6 (86) 75.0 (3) 41.9 (36)
4 1 0 0 0 1 0 5.2 (4) 94.8 (73) 75.0 (3) 42.5 (31)
5 1 0 0 0 0 1 10.9 (7) 89.1 (57) 28.6 (2) 26.3 (15)
6 1 0 0 0 1 1 4.1 (3) 95.9 (71) 33.3 (1) 42.3 (30)
7 0 0 0 0 0 1 12.5 (2) 87.5 (14) 100 (2) 42.9 (6)
8 0 0 0 0 1 1 7.7 (1) 92.3 (12) 0 (0) 33.3 (4)
9 0 0 1 0 0 0 50 (2) 50 (2) 100 (2) 50 (1)
10 0 1 0 0 0 0 20 (1) 80 (4) 100 (1) 100 (4)
11 1 0 1 0 1 0 10 (1) 90 (9) 100 (1) 66.7 (6)
12 1 0 1 0 1 1 20 (1) 80 (4) 100 (1) 50 (2)
13 1 0 1 0 1 2 20 (1) 80 (4) 100 (1) 100 (4)
Any TAM K65R L74V Q151M M184V NNRTI mutationsb
14 0 0 0 0 0 0 16.3 (24) 83.7 (123) 62.5 (15) 50.4 (62)
15 0 0 0 0 0 1 50 (1) 50 (1) 100 (1) 100 (1)
16 0 0 0 0 1 0 12.5 (2) 87.5 (14) 0 (0) 57.1 (8)
17 1 0 0 0 1 0 6.9 (2) 93.1 (27) 50 (1) 18.5 (5)
HAART, highly active antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TAM, thymidine analogue mutation.
a0, no mutations; 1, 1–3 mutations; 2, >3 mutations.
b0, no mutations; 1, any mutations.
CMI Research Note E69
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E66–E70
(grant 30G.44 to C. Balotta), Ministero della Salute, Ricerca
Corrente (grant 80207 to S. Paolucci), Programma Nazionale
AIDS 2009 (grant 40H81 to M. Zazzi), and the European
Community’s Seventh Framework Programme (FP7/2007–
2013) under the project ‘Collaborative HIV and Anti-HIV
Drug Resistance Network (CHAIN)’ (grant agreement num-
ber 223131).
Transparency Declaration
The authors have no conﬂicting interests regarding this
work. A part of the results has been previously presented at
the ‘International HIV and Hepatitis virus drug resistance
workshop and curative strategies’, Dubrovnik, June 8–12
2010.
References
1. Monno L, Brindicci G, Lo Caputo S et al. HIV-1 subtypes and circulat-
ing recombinant forms (CRFs) from HIV-infected patients residing in
two regions of central and southern Italy. J Med Virol 2005; 75: 483–
490.
2. Balotta C, Facchi G, Violin M et al. Increasing prevalence of non-cla-
de B HIV-1 strains in heterosexual men and women, as monitored by
analysis of reverse transcriptase and protease sequences. J Acquir
Immune Deﬁc Syndr 2001; 27: 499–505.
3. Lai A, Riva C, Marconi A et al. Changing patterns in HIV-1 non-
B clade prevalence and diversity in Italy over three decades. HIV Med
2010; 11: 593–602.
4. Baldanti F, Paolucci S, Ravasi G et al. Changes in circulation of B and
non-B HIV strains: spotlight on a reference centre for infectious dis-
eases in northern Italy. J Med Virol 2008; 80: 947–952.
5. Riva C, Lai A, Caramma I et al. Transmitted HIV type 1 drug resis-
tance and non-B subtype prevalence among seroconverters and
newly diagnosed patients from 1992 to 2005 in Italy. AIDS Res Hum
Retroviruses 2010; 26: 41–49.
6. Frater AJ, Dunn DT, Beardall AJ et al. Comparative response of Afri-
can HIV-1-infected individuals to highly active antiretroviral therapy.
AIDS 2002; 16: 1139–1146.
7. Atlas A, Granath F, Lindstrom A et al. Impact of HIV type 1 genetic
subtype on the outcome of antiretroviral therapy. AIDS Res Hum Ret-
roviruses 2005; 21: 221–227.
8. De Wit S, Boulme¢ R, Poll B et al. Viral load and CD4 cell response
to protease inhibitor-containing regimens in subtype B versus non-B
treatment-naive HIV-1 patients. AIDS 2004; 18: 2330–2331.
9. Bocket L, Cheret A, Deufﬁc-Burban S et al. Impact of human immu-
nodeﬁciency virus type 1 subtype on ﬁrst-line antiretroviral therapy
effectiveness. Antiviral Ther 2005; 10: 247–254.
10. Bannister WP, Ruiz L, Loveday C et al. HIV-1 subtypes and response
to combination antiretroviral therapy in Europe. Antiviral Ther 2006;
11: 707–715.
11. Cassol E, Page T, Mosam A et al. Therapeutic response of HIV-1 sub-
type C in African patients coinfected with either Mycobacterium tuber-
culosis or human herpesvirus-8. J Infect Dis 2005; 191: 324–332.
12. Garrido C, Zahonero N, Fernandes D et al. Subtype variability, viro-
logical response and drug resistance assessed on dried blood spots
collected from HIV patients on antiretroviral therapy in Angola. J An-
timicrob Chemother 2008; 61: 694–698.
13. Geretti AM, Harrison L, Green H et al. Effect of HIV-1 subtype on
virologic and immunologic response to starting highly active antiret-
roviral therapy. Clin Infect Dis 2009; 48: 1296–1305.
14. Easterbrook PJ, Smith M, Mullen J et al. Impact of HIV-1 viral subtype
on disease progression and response to antiretroviral therapy. J Int
AIDS Soc 2010; 13: 4.
15. Kantor R, Katzenstein DA, Efron B et al. Impact of HIV-1 subtype
and antiretroviral therapy on protease and reverse transcriptase
genotype: results of a global collaboration. PLoS Med 2005; 2: 325–
337.
16. Monno L, Scudeller L, Brindicci G et al. Genotypic analysis of the
protease and reverse transcriptase of non-B HIV type 1 clinical
isolates from naı¨ve and treated subjects. Antiviral Res 2009; 83:
118–126.
17. Shahriar R, Rhee SY, Liu TF et al. Nonpolymorphic human immu-
nodeﬁciency virus type 1 protease and reverse transcriptase treat-
ment-selected mutations. Antimicrob Agents Chemother 2009; 53:
4869–4878.
18. Bandaranayake RM, Kolli M, King NM et al. The effect of clade-spe-
ciﬁc sequence polymorphisms on HIV-1 protease activity and inhibi-
tor resistance pathways. J Virol 2010; 84: 9995–10003.
19. Snoeck J, Kantor R, Shafer RW et al. Discordances between interpre-
tation algorithms for genotypic resistance to protease and reverse
transcriptase inhibitors of human immunodeﬁciency virus are subtype
dependent. Antimicrob Agents Chemother 2006; 50: 694–701.
20. Camacho RJ, Vandamme AM. Antiretroviral resistance in different
HIV-1 subtypes: impact on therapy outcomes and resistance testing
interpretation. Curr Opin HIV AIDS 2007; 2: 123–129.
E70 Clinical Microbiology and Infection, Volume 18 Number 3, March 2012 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E66–E70
